<DOC>
	<DOCNO>NCT01170936</DOCNO>
	<brief_summary>This single-center open label study assess efficacy safety single dos canakinumab ( trade name Ilaris® ) , high-affinity monoclonal antibody neutralize IL-1β , patient active urticarial vasculitis . Efficacy primarily assess combined symptom score , urticarial vasculitis activity score ( UVAS ) . Following baseline period 2 week , patient dose two single s.c. injection 150 mg ( consistent total dose 300 mg canakinumab ) . Visits investigator 's assessment schedule 1 week , 2 week , 4 week , 8 week , 12 week 16 week post dose . Patient 's self-assessment performed daily basis throughout study . Overall max . 10 subject urticarial vasculitis enrol .</brief_summary>
	<brief_title>Ilaris® Urticarial Vasculitis - Investigation Treatment Responses</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Vasculitis , Leukocytoclastic , Cutaneous</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults ( 18 year old ) UV diagnosis base diagnostic criterion define Appendix 3 Active UV , refractory treatment antihistamine , NSAIDS colchicine , hydroxychloroquine dapsone Patients mean symptom score ( UVAS ) least 5 baseline If necessary , concurrent/ongoing treatment stable dose systemic corticosteroid great 10mg/d 14 day prior screen If necessary , concurrent/ongoing treatment stable dose antihistamine NSAIDs 7 day prior screen Informed consent sign date Able read , understand willing sign inform consent form abide study procedure Willing , commit able return clinic visit complete studyrelated procedure , include willingness SC injection administer qualified person In female childbearing potential : Negative pregnancy test ; male female willing use highly effective contraception ( PearlIndex &lt; 1 ) . A woman consider childbearing potential postmenopausal great two year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) In men : Willingness utilize highly effective contraception partner become pregnant full course study . Adequate contraceptive measure include oral contraceptive ( stable use two cycle prior screen ) ; bilateral tubal ligation ; vasectomy ; condom diaphragm plus either contraceptive sponge , foam jelly Subjects consider eligible , meet following tuberculosis ( TB ) screen criterion : history latent active TB prior screen , sign symptom suggestive active TB , recent close contact person active TB , negative QuantiFERONTB test screening ( QuantiFERONTB test positive , patient include active TB rule appropriate measurement accord standard care ) . No participation clinical trial 4 week participation study Concurrent/ongoing treatment Anakinra ( Kineret® ) recent treatment within 3 day prior screen Concurrent/ongoing treatment biologics recent treatment ( less 5 half life ) Concurrent/ongoing treatment oral corticosteroid great 10 mg/d within 2 week prior screen parenteral corticosteroid within 4 week prior screen cyclosporin A , methotrexate , dapsone , chloroquine , hydroxychloroquine , azathioprine , cyclophosphamide within 4 week prior screen immunosuppressive within 4 week 5 half life prior screen , whichever long Evidence recurrent latent systemic infection tuberculosis Significant medical condition render patient immunocompromised suitable clinical trial Treatment live ( attenuate ) virus vaccine three month prior Baseline visit ( Visit 2 ) An abnormal chest radiograph consistent clinical sign prior present tuberculosis infection whether previously treat antituberculosis agent A history listeriosis , active tuberculosis , persistent chronic active infection ( ) require treatment parenteral antibiotic , parenteral antiviral , parenteral antifungal within four week prior screen Significant concomitant illness , limited , cardiac , renal , neurological , endocrinological , metabolic , lymphatic disease would adversely affect subject 's participation evaluation study Active systemic inflammatory condition UV include , limited , rheumatoid arthritis , systemic lupus erythematosus Sjögren 's Syndrome History fibromyalgia chronic fatigue syndrome Evidence current HIV , active hepatitis B , hepatitis C infection clinical serological history History malignancy within five year prior screen successfully treat nonmetastatic cutaneous , basal , squamous cell carcinoma and/or situ cervical cancer History demyelinate disease multiple sclerosis Severe respiratory disease , include , limited severe bronchiectasis , chronic obstructive pulmonary disease , bullous lung disease , uncontrolled asthma , pulmonary fibrosis Presence follow laboratory abnormality enrollment visit : creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) , WBC &lt; 3000/µl ; platelet count &lt; 100000/µl ; ALT AST &gt; 3.0 x ULN Lactating female pregnant female Males willing use highly effective contraception Enrollment another investigational treatment device study use investigational agent , less 4 week 5 halflives , whichever longer , since end another investigational device drug trial Subjects concern compliance protocol procedures Any medical condition , opinion Investigator , would interfere participation study place subject risk History substance abuse ( drug alcohol ) factor ( e.g. , serious psychiatric condition ) could limit subject 's ability comply study procedure Subjects detain officially legally official institute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Urticarial vasculitis</keyword>
	<keyword>anti-IL1ß therapy</keyword>
</DOC>